1
|
Arish M, Naz F. Sphingosine-1-phosphate receptors 2 and 3 reprogram resting human macrophages into M1 phenotype following mycobacteria infection. CURRENT RESEARCH IN IMMUNOLOGY 2022; 3:110-117. [PMID: 35676924 PMCID: PMC9168381 DOI: 10.1016/j.crimmu.2022.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 04/14/2022] [Accepted: 05/17/2022] [Indexed: 11/22/2022] Open
Abstract
Mycobacteria tuberculosis (M.tb) the causative agent for tuberculosis has been accredited for a high rate of morbidity and mortality worldwide. The rise in MDR and XDR cases has further created new obstacles in achieving the "End TB Strategy", which is aimed for 2035. In this article, we have demonstrated the potential of sphingosine-1-phosphate (S1P) analogs in providing an anti-mycobacterial effector response by altering macrophage polarity into M1. Among S1PR1 and S1PR3 analogs, S1PR2 analogs proficiently favor selective polarization of infected human macrophages into M1 phenotypes, marked by increased expression of M1 markers and decreased M2 markers. Furthermore, S1PR1-3 analogs treated macrophages were also able to decrease the secretion of anti-inflammatory cytokine IL-10 and can induce NO secretion in infected macrophages. Lastly, only S1PR2-3 analogs were able to restrict the growth of mycobacteria in human macrophages. Taken together our study reflects the potential of S1PR2-3 analogs in providing host defenses following mycobacterial infection by favoring M1 macrophage polarization.
Collapse
Affiliation(s)
- Mohd Arish
- JH-Institute of Molecular Medicine, Jamia Hamdard, New Delhi, India
| | - Farha Naz
- Centre of Interdisciplinary Research in Basic Science (CIRBSc), Jamia Millia Islamia, New Delhi, India
| |
Collapse
|
2
|
Park SJ, Yeon SK, Kim Y, Kim HJ, Kim S, Kim J, Choi JW, Kim B, Lee EH, Kim R, Seo SH, Lee J, Kim JW, Lee HY, Hwang H, Bahn YS, Cheong E, Park JH, Park KD. Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis. J Med Chem 2022; 65:3539-3562. [PMID: 35077170 DOI: 10.1021/acs.jmedchem.1c01979] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The sphingosine-1-phosphate-1 (S1P1) receptor agonists have great potential for the treatment of multiple sclerosis (MS) because they can inhibit lymphocyte egress through receptor internalization. We designed and synthesized triazole and isoxazoline derivatives to discover a novel S1P1 agonist for MS treatment. Of the two scaffolds, the isoxazoline derivative was determined to have excellent in vitro efficacy and drug-like properties. Among them, compound 21l was found to have superior drug-like properties as well as excellent in vitro efficacies (EC50 = 7.03 nM in β-arrestin recruitment and EC50 = 11.8 nM in internalization). We also confirmed that 21l effectively inhibited lymphocyte egress in the peripheral lymphocyte count test and significantly improved the clinical score in the experimental autoimmune encephalitis MS mouse model.
Collapse
Affiliation(s)
- Sun Jun Park
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea.,Cureverse Co., Ltd., KIST, 1st Floor, H2 Building, Seoul 02792, Republic of Korea
| | - Seul Ki Yeon
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea
| | - Yoowon Kim
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
| | - Hyeon Jeong Kim
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
| | - Siwon Kim
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea
| | - Jushin Kim
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
| | - Ji Won Choi
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea
| | - Byungeun Kim
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea
| | - Elijah Hwejin Lee
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea
| | - Rium Kim
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea
| | - Seon Hee Seo
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea
| | - Jaeick Lee
- Doping Control Center, KIST, Seoul 02792, Republic of Korea
| | - Jun Woo Kim
- New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu 41061, Republic of Korea
| | - Ha-Yeon Lee
- New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu 41061, Republic of Korea
| | - Hayoung Hwang
- New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu 41061, Republic of Korea
| | - Yong-Sun Bahn
- Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
| | - Eunji Cheong
- Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea
| | - Jong-Hyun Park
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea
| | - Ki Duk Park
- Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology (KIST), Seoul 02792, Republic of Korea.,Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea
| |
Collapse
|
3
|
Chen HL, Huang X, Yao D, Wang Y, Lu X. Synthesis and crystal structure of 5-(8-((3-carboxyazetidin-1-ium-1-yl)methyl)-7-hydroxy-4-oxo-4 H-chromen-3-yl)-2-hydroxybenzenesulfonate monohydrate, C 20H 19NO 10S. Z KRIST-NEW CRYST ST 2021. [DOI: 10.1515/ncrs-2021-0346] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
C20H19NO10S, triclinic,
P
1
‾
$P‾{1}$
(no. 2), a = 8.3470(2) Å, b = 9.6701(2) Å, c = 12.9523(3) Å, α = 102.413(2)°, β = 103.199(2)°, γ = 97.753(2)°, V = 975.26(4) Å3, Z = 2, R
gt(F) = 0.0439, wR
ref(F
2) = 0.1244, T = 100(1) K.
Collapse
Affiliation(s)
- Hai-Lin Chen
- School of Chemical and Biological Engineering , Hechi University , Yizhou , Guangxi , 546300 , China
| | - Xiu‑Xiang Huang
- School of Chemical and Biological Engineering , Hechi University , Yizhou , Guangxi , 546300 , China
| | - Dong‑Mei Yao
- School of Chemical and Biological Engineering , Hechi University , Yizhou , Guangxi , 546300 , China
| | - Yan‑Ping Wang
- School of Chemical and Biological Engineering , Hechi University , Yizhou , Guangxi , 546300 , China
| | - Xiao‑Bing Lu
- School of Chemical and Biological Engineering , Hechi University , Yizhou , Guangxi , 546300 , China
| |
Collapse
|
4
|
Yip SH, Wu D, Kempson J, Hernandez A, Zhang H, Li P, Sun D, Mathur A. Large‐scale chiral supercritical fluid chromatography of a key intermediate in the synthesis of two S1P
1
final active pharmaceutical ingredients. SEPARATION SCIENCE PLUS 2019. [DOI: 10.1002/sscp.201900047] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Shiuhang Henry Yip
- Department of Discovery SynthesisResearch and DevelopmentBristol‐Myers Squibb Co Princeton NJ USA
| | - Dauh‐Rurng Wu
- Department of Discovery SynthesisResearch and DevelopmentBristol‐Myers Squibb Co Princeton NJ USA
| | - James Kempson
- Department of Discovery SynthesisResearch and DevelopmentBristol‐Myers Squibb Co Princeton NJ USA
| | - Andres Hernandez
- Department of Discovery SynthesisResearch and DevelopmentBristol‐Myers Squibb Co Princeton NJ USA
| | - Huiping Zhang
- Department of Discovery SynthesisResearch and DevelopmentBristol‐Myers Squibb Co Princeton NJ USA
| | - Peng Li
- Department of Discovery SynthesisResearch and DevelopmentBristol‐Myers Squibb Co Princeton NJ USA
| | - Dawn Sun
- Department of Discovery SynthesisResearch and DevelopmentBristol‐Myers Squibb Co Princeton NJ USA
| | - Arvind Mathur
- Department of Discovery SynthesisResearch and DevelopmentBristol‐Myers Squibb Co Princeton NJ USA
| |
Collapse
|
5
|
Vestri A, Pierucci F, Frati A, Monaco L, Meacci E. Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis? Front Pharmacol 2017. [PMID: 28626422 PMCID: PMC5454082 DOI: 10.3389/fphar.2017.00296] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Sphingosine 1-phosphate (S1P) is a bioactive lipid that is characterized by a peculiar mechanism of action. In fact, S1P, which is produced inside the cell, can act as an intracellular mediator, whereas after its export outside the cell, it can act as ligand of specific G-protein coupled receptors, which were initially named endothelial differentiation gene (Edg) and eventually renamed sphingosine 1-phosphate receptors (S1PRs). Among the five S1PR subtypes, S1PR1, S1PR2 and S1PR3 isoforms show broad tissue gene expression, while S1PR4 is primarily expressed in immune system cells, and S1PR5 is expressed in the central nervous system. There is accumulating evidence for the important role of S1P as a mediator of many processes, such as angiogenesis, carcinogenesis and immunity, and, ultimately, fibrosis. After a tissue injury, the imbalance between the production of extracellular matrix (ECM) and its degradation, which occurs due to chronic inflammatory conditions, leads to an accumulation of ECM and, consequential, organ dysfunction. In these pathological conditions, many factors have been described to act as pro- and anti-fibrotic agents, including S1P. This bioactive lipid exhibits both pro- and anti-fibrotic effects, depending on its site of action. In this review, after a brief description of sphingolipid metabolism and signaling, we emphasize the involvement of the S1P/S1PR axis and the downstream signaling pathways in the development of fibrosis. The current knowledge of the therapeutic potential of S1PR subtype modulators in the treatment of the cardiac functions and fibrinogenesis are also examined.
Collapse
Affiliation(s)
- Ambra Vestri
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Molecular and Applied Biology Research Unit, University of FlorenceFlorence, Italy
| | - Federica Pierucci
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Molecular and Applied Biology Research Unit, University of FlorenceFlorence, Italy.,Interuniversity Institutes of MyologyFirenze, Italy
| | - Alessia Frati
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Molecular and Applied Biology Research Unit, University of FlorenceFlorence, Italy
| | - Lucia Monaco
- Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of RomeRome, Italy
| | - Elisabetta Meacci
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Molecular and Applied Biology Research Unit, University of FlorenceFlorence, Italy.,Interuniversity Institutes of MyologyFirenze, Italy
| |
Collapse
|
6
|
Dyckman AJ. Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P 1) Agonists and Future Perspectives. J Med Chem 2017; 60:5267-5289. [PMID: 28291340 DOI: 10.1021/acs.jmedchem.6b01575] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The sphingoid base derived class of lipids (sphingolipids) is a family of interconverting molecules that play key roles in numerous structural and signaling processes. The biosynthetic pathway of the sphingolipids affords many opportunities for therapeutic intervention: targeting the ligands directly, targeting the various proteins involved in the interconversion of the ligands, or targeting the receptors that respond to the ligands. The focus of this article is on the most advanced of the sphingosine-related therapeutics, agonists of sphingosine-1-phosphate receptor 1 (S1P1). The diverse structural classes of S1P1 agonists will be discussed and the status of compounds of clinical relevance will be detailed. An examination of how potential safety concerns are being navigated with compounds currently under clinical evaluation is followed by a discussion of the novel methods being explored to identify next-generation S1P1 agonists with improved safety profiles. Finally, therapeutic opportunities for sphingosine-related targets outside of S1P1 are touched upon.
Collapse
Affiliation(s)
- Alaric J Dyckman
- Research and Development, Bristol-Myers Squibb Company , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
7
|
Marcoux D, Xiao HY, Murali Dhar TG, Xie J, Lehman-McKeeman LD, Wu DR, Dabros M, Yang X, Taylor TL, Zhou XD, Heimrich EM, Thomas R, McIntyre KW, Shi H, Levesque PC, Sun H, Yang Z, Marino AM, Cornelius G, D'Arienzo CJ, Gupta A, Pragalathan B, Rampulla R, Mathur A, Shen DR, Cvijic ME, Salter-Cid L, Lombardo LJ, Carter PH, Dyckman AJ. Identification of potent tricyclic prodrug S1P 1 receptor modulators. MEDCHEMCOMM 2016; 8:725-729. [PMID: 30108791 DOI: 10.1039/c6md00539j] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Accepted: 11/21/2016] [Indexed: 12/31/2022]
Abstract
Recently, our research group reported the identification of prodrug amino-alcohol 2 as a potent and efficacious S1P1 receptor modulator. This molecule is differentiated preclinically over the marketed drug fingolimod (Gilenya 1), whose active phosphate metabolite is an S1P1 full agonist, in terms of pulmonary and cardiovascular safety. S1P1 partial agonist 2, however, has a long half-life in rodents and was projected to have a long half-life in humans. The purpose of this communication is to disclose highly potent partial agonists of S1P1 with shorter half-lives relative to the clinical compound 2. PK/PD relationships as well as their preclinical pulmonary and cardiovascular safety assessment are discussed.
Collapse
Affiliation(s)
- David Marcoux
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Hai-Yun Xiao
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - T G Murali Dhar
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Jenny Xie
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Lois D Lehman-McKeeman
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Dauh-Rurng Wu
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Marta Dabros
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Xiaoxia Yang
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Tracy L Taylor
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Xia D Zhou
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Elizabeth M Heimrich
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Rochelle Thomas
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Kim W McIntyre
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Hong Shi
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Paul C Levesque
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Huadong Sun
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Zheng Yang
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Anthony M Marino
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Georgia Cornelius
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Celia J D'Arienzo
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | | | | | - Richard Rampulla
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Arvind Mathur
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Ding Ren Shen
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Mary Ellen Cvijic
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Luisa Salter-Cid
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Louis J Lombardo
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Percy H Carter
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Alaric J Dyckman
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| |
Collapse
|